Patient-specific induced pluripotent stem-cell models for long-QT syndrome.

By A. Moretti, M. Bellin, A. Welling, C. Jung, J. Lam, Lorenz Bott-Flügel, Tatjana Dorn, A. Goedel, C. Höhnke, F. Hofmann and 4 more. New England Journal of Medicine, 2010

1,245 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/4a4ead8cc2068d34c6a71597f5885137986ab67d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. G. Daley
2. A. Sachinidis
3. M. Doss
4. Daisy A. Robinton
5. E. Morrisey
6. James A. Thomson
7. G. Keller

Citations in the corpus

• The promise of induced pluripotent stem cells in research and therapy (2012, background): “In a proof-of-principle study for using iPS cells to capture the physiological mechanisms of genetic variation, Moretti and colleagues differentiated iPS cells from individuals with type 1 long QT syndrome into cardiomyocytes and, as predicted, observed prolonged action potentials in the ventricular”
• Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming (2012, neutral): “Studies to date have largely concentrated on recapitulating genetic disease phenotypes in vitro, such as long QT syndromes (Itzhaki et al., 2011a; Matsa et al., 2011; Moretti et al., 2010), Timothy syndrome (Yazawa et al., 2011), and LEOPARD syndrome (Carvajal-Vergara et al., 2010).”
• High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. (2011, background): “(29) demonstrated that both IKr and IKs were present in hiPSC-derived cardiomyocytes.”
• Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency (2011, positive): “…cell biology, but also in the ability to generate patient-specific iPSC clones, which can then be further differentiated into the cell lineage of choice, including hematopoietic, cardiomyocyte, and hepatocyte cell lineages (Moretti et al., 2010a, 2010b; Raya et al., 2010; Si-Tayeb et al., 2010).”
• Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications (2019, methodology): “iPSC-based disease modelling has been widely used for early-onset diseases and proved to be successful models for early onset diseases such as long QT syndrome and spinal muscular atrophy [99,100].”